LCR Ventures says UK health-tech founders face tougher NHS traction scrutiny as Q2 2026 biotech funding hits £2.05 billion
XLV•LCR Ventures said UK biotech venture funding reached £2.05 billion in Q2 2026, its strongest level in five years, largely driven by Isomorphic Labs’ £1.6 billion Series B; excluding that round, funding was £498 million.
1. Funding and investor focus
LCR Ventures said UK biotech venture investment reached £2.05 billion in Q2 2026, the strongest level in five years. Isomorphic Labs’ £1.6 billion Series B accounted for most of the total; excluding it, funding was £498 million, nearly double year-ago levels. The analysis said investors are prioritizing commercial traction over technical promise as competition for capital intensifies across UK health-tech.
2. NHS access routes
The analysis highlighted expanded NHS access routes, including the Regulatory Airlock rollout to Manchester University NHS Foundation Trust on Sept. 4. A planned Innovator Passport via MedTech Compass aims to reduce repeat NHS compliance reviews and potentially speed multi-trust adoption.
